Q-omics provides the consensus-scored LDHAP5 profile across patient tissues and cancer cell-line models. LDHAP5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LDHAP5 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, LDHAP5 RNA expression shows 15,864 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where LDHAP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LDHAP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LDHAP5 survival associations across molecular data types. LDHAP5 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LDHAP5 RNA expression–survival associations across cancer types. High LDHAP5 expression shows unfavorable associations in UVM, LUAD, PAAD and KICH, but favorable associations in KIRC and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LDHAP5 RNA expression.
This table summarizes LDHAP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LDHAP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LDHAP5 shows higher tumor expression in KIRC, LUSC, LUAD, HNSC, COAD and UCEC. The KIRC box plot shows higher LDHAP5 RNA expression in tumor versus normal tissue (log2 FC = +0.996, t-test p < 0.001).
This table shows molecular features associated with LDHAP5 in patient tissues and cancer cell lines. In patient samples, LDHAP5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
